| A |
B |
| Disease |
| Brucellosis |
" Arthritis. |
|
" Cardiovascular, nervous, and respiratory system infections. |
|
" Chronic meningitis and meningoencephalitis. |
|
" Deafness. |
|
" Demyelinating meningovascular syndromes. |
|
" Episcleritis. |
|
" Fatigue, inattention, amnesia, and depression. |
|
" Guillain-Barre syndrome. |
|
" Hepatic abnormalities, including granulomatous hepatitis. |
|
" Multifocal choroiditis. |
|
" Myelitis-radiculoneuritis. |
|
" Nummular keratitis. |
|
" Papilledema. |
|
" Optic neuritis. |
|
" Orchioepididymitis and infections of the genitourinary system. |
|
" Sensorineural hearing loss. |
|
" Spondylitis. |
|
" Uveitis. |
| Campylobacter jejuni |
" Guillain-Barre syndrome if manifest within 2 months of the infection. |
|
" Reactive Arthritis if manifest within 3 months of the infection. |
|
" Uveitis if manifest within 1 month of the infection. |
| Coxiella burnetii (Q fever) |
" Chronic hepatitis. |
|
" Endocarditis. |
|
" Osteomyelitis. |
|
" Post-Q-fever chronic fatigue syndrome. |
|
" Vascular infection. |
| Malaria |
" Demyelinating polyneuropathy. |
|
" Guillain-Barre syndrome. |
|
" Hematologic manifestations (particularly anemia after falciparum malaria and splenic rupture after vivax malaria). |
|
" Immune-complex glomerulonephritis. |
|
" Neurologic disease, neuropsychiatric disease, or both. |
|
" Ophthalmologic manifestations, particularly retinal hemorrhage and scarring. |
|
" Plasmodium falciparum. |
|
" Plasmodium malariae. |
|
" Plasmodium ovale. |
|
" Plasmodium vivax. |
|
" Renal disease, especially nephrotic syndrome. |
| Mycobacterium tuberculosis |
" Active tuberculosis. |
|
" Long-term adverse health outcomes due to irreversible tissue damage from severe forms of pulmonary and extrapulmonary tuberculosis and active tuberculosis. |
| Nontyphoid Salmonella |
" Reactive Arthritis if manifest within 3 months of the infection. |
| Shigella |
" Hemolytic-uremic syndrome if manifest within 1 month of the infection. |
|
" Reactive Arthritis if manifest within 3 months of the infection. |
| Visceral leishmaniasis |
" Delayed presentation of the acute clinical syndrome. |
|
" Post-kala-azar dermal leishmaniasis if manifest within 2 years of the infection. |
|
" Reactivation of visceral leishmaniasis in the context of future immunosuppression. |
| West Nile virus |
" Variable physical, functional, or cognitive disability. |